First National Trust Co reduced its holdings in Eli Lilly and Co (NYSE:LLY) by 6.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 61,167 shares of the company’s stock after selling 4,299 shares during the period. First National Trust Co’s holdings in Eli Lilly and were worth $5,166,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. Airain ltd bought a new position in Eli Lilly and in the 2nd quarter worth approximately $567,000. Buckingham Asset Management LLC increased its position in Eli Lilly and by 21.3% in the 2nd quarter. Buckingham Asset Management LLC now owns 3,232 shares of the company’s stock worth $266,000 after buying an additional 568 shares during the period. BSW Wealth Partners increased its position in Eli Lilly and by 0.6% in the 2nd quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock worth $393,000 after buying an additional 27 shares during the period. Mirador Capital Partners LP increased its position in Eli Lilly and by 5.3% in the 2nd quarter. Mirador Capital Partners LP now owns 12,280 shares of the company’s stock worth $1,011,000 after buying an additional 619 shares during the period. Finally, Candriam Luxembourg S.C.A. increased its position in Eli Lilly and by 166.7% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 430,424 shares of the company’s stock worth $36,818,000 after buying an additional 269,038 shares during the period. 76.35% of the stock is currently owned by institutional investors.
Shares of Eli Lilly and Co (LLY) traded up $0.70 during mid-day trading on Wednesday, reaching $85.99. The company had a trading volume of 1,892,400 shares, compared to its average volume of 2,955,040. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The firm has a market cap of $94,770.00, a price-to-earnings ratio of 40.95, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. Eli Lilly and Co has a twelve month low of $74.00 and a twelve month high of $89.09.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be paid a $0.5625 dividend. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $2.25 annualized dividend and a yield of 2.62%. Eli Lilly and’s payout ratio is currently 99.05%.
Several brokerages have recently weighed in on LLY. Jefferies Group set a $100.00 price objective on Eli Lilly and and gave the stock a “buy” rating in a report on Tuesday. Goldman Sachs Group lowered Eli Lilly and from a “buy” rating to a “neutral” rating and lifted their price objective for the stock from $86.98 to $95.00 in a report on Tuesday. BMO Capital Markets reissued a “sell” rating and set a $71.00 price objective on shares of Eli Lilly and in a report on Thursday, September 28th. Cowen reissued a “buy” rating and set a $95.00 price objective on shares of Eli Lilly and in a report on Wednesday, October 4th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $105.00 price objective on shares of Eli Lilly and in a report on Friday, October 13th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the stock. Eli Lilly and presently has an average rating of “Hold” and a consensus price target of $92.75.
In related news, SVP Susan Mahony sold 36,585 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $86.18, for a total value of $3,152,895.30. Following the sale, the senior vice president now owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the business’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now directly owns 43,580 shares in the company, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 251,088 shares of company stock worth $22,041,236. 0.20% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: This story was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3142815/eli-lilly-and-co-lly-holdings-reduced-by-first-national-trust-co.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.